Skip to main content
NewslettersWatchlist

Revance Therapeutics(RVNC-Q)
NASDAQ

Today's Change
Delayed Last Update
Day Low3.65
Day High3.66
Open:3.65
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

TOP STORIES: Revance Therapeutics

Select a category then submit the form to load news
TheNewswire.com
SHAREHOLDER ALERT: Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Revance Therapeutics, Inc. (RVNC) - Deadline is March 4, 2025
TheNewswire.com
INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Revance Therapeutics, Inc. (RVNC) - Deadline is March 4, 2025
TheNewswire.com
Lead Plaintiff Deadline is March 4, 2025 for Investors of Revance Therapeutics, Inc. (RVNC) - Contact Kaplan Fox
TheNewswire.com
Kaplan Fox Alerts Investors of Revance Therapeutics to the Lead Plaintiff Deadline on March 4, 2025
TheNewswire.com
Securities Class Action Lawsuit Against Revance Therapeutics, Inc. (RVNC) - Contact Kaplan Fox Before Deadline on March 4, 2025
TheNewswire.com
RVNC DEADLINE ALERT: Revance Therapeutics Investors Are Encouraged to Contact Kaplan Fox Before Lead Plaintiff Deadline on March 4, 2025
TheNewswire.com
REVANCE THERAPEUTICS INVESTOR ALERT: Kaplan Fox Alerts Investors of a Class Action Deadline on March 4, 2025
TheNewswire.com
RVNC SHAREHOLDER ALERT: Deadline to Lead in Securities Fraud Lawsuit Against Revance Therapeutics, Inc. (RVNC) is March 4, 2025 - Contact Kaplan Fox
TheNewswire.com
Kaplan Fox Alerts Revance Therapeutics Investors to a Securities Class Action Lawsuit - Deadline is March 4, 2025
TheNewswire.com
RVNC DEADLINE ALERT: Kaplan Fox Reminds Investors of a Class Action Lawsuit Against Revance Therapeutics, Inc. (RVNC) and Lead Plaintiff Deadline on March 4, 2025
TheNewswire.com
RVNC SHAREHOLDER ACTION ALERT: Kaplan Fox Reminds Investors of a Class Action Lawsuit Against Revance Therapeutics, Inc. (RVNC) and Lead Plaintiff Deadline on March 4, 2025
TheNewswire.com
RVNC DEADLINE FOR LEADERSHIP is March 4, 2025 in a Securities Fraud Lawsuit - Contact Kaplan Fox
TheNewswire.com
RVNC CLASS ACTION DEADLINE: Kaplan Fox Reminds Investors of a Class Action Lawsuit Against Revance Therapeutics, Inc. (RVNC) and Lead Plaintiff Deadline on March 4, 2025
TheNewswire.com
REVANCE THERAPEUTICS DEADLINE FOR LEADERSHIP is March 4, 2025 in a Securities Fraud Lawsuit - Contact Kaplan Fox & Kilsheimer LLP
TheNewswire.com
RVNC DEADLINE: Investors of Revance Therapeutics, Inc. Are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on March 4, 2025
ACCESS Newswire
Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)
TheNewswire.com
Kaplan Fox Alerts Revance Therapeutics, Inc. (RVNC) Investors to a Securities Class Action Lawsuit - Deadline is March 4, 2025
TheNewswire.com
RVNC DEADLINE: Investors Are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on March 4, 2025
TheNewswire.com
RVNC Deadline to Lead in Securities Fraud Lawsuit is March 4, 2025 - Contact Kaplan Fox & Kilsheimer LLP
TheNewswire.com
Deadline to Lead in Securities Fraud Lawsuit Against Revance Therapeutics, Inc. (RVNC) is March 4, 2025 - Contact Kaplan Fox & Kilsheimer LLP
TheNewswire.com
Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Revance Therapeutics, Inc. (RVNC) - Deadline is March 4, 2025
Motley Fool
AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revance Therapeutics, Inc. - RVNC
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revance Therapeutics, Inc. - RVNC
Business Wire
Revance to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023
Business Wire
Revance to Participate in the Needham 22nd Annual Healthcare Conference
Business Wire
Revance Publishes its 2022 Environmental, Social, and Governance (ESG) Report
Business Wire
Revance to Participate in Upcoming Investor Conferences
MarketBeat
Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor
Business Wire
Revance Reports Fourth Quarter and Full Year 2022 Financial Results, Provides Corporate Update
Business Wire
Revance Adds Experienced Pharmaceutical Executive to Board of Directors with Appointment of Dr. Vlad Coric, M.D., as Independent Director
Business Wire
Revance to Participate in the 43rd Annual Cowen Healthcare Conference

Profile

Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS' peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2025.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2025 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.